OTCMKTS:NURPF Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis C$8.45 0.00 (0.00%) (As of 11/7/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort Interest About Neuren Pharmaceuticals Stock (OTCMKTS:NURPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neuren Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$8.45▼C$8.4550-Day RangeC$6.61▼C$10.3352-Week RangeC$6.61▼C$17.21VolumeN/AAverage Volume3,219 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More… The secret supplier behind NVIDIA, Tesla and Microsoft (Ad)The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> Neuren Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks1st Percentile Overall ScoreNURPF MarketRank™: Neuren Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Neuren Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuren Pharmaceuticals is -944.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuren Pharmaceuticals is -944.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverNeuren Pharmaceuticals has a short interest ratio ("days to cover") of 2429.5, which indicates bearish sentiment.Change versus previous monthShort interest in Neuren Pharmaceuticals has recently decreased by 1.94%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuren Pharmaceuticals does not currently pay a dividend.Dividend GrowthNeuren Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverNeuren Pharmaceuticals has a short interest ratio ("days to cover") of 2429.5, which indicates bearish sentiment.Change versus previous monthShort interest in Neuren Pharmaceuticals has recently decreased by 1.94%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.34 News SentimentNeuren Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Neuren Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuren Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.74% of the stock of Neuren Pharmaceuticals is held by institutions.Read more about Neuren Pharmaceuticals' insider trading history. Receive NURPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NURPF Stock News HeadlinesHealth Check: Neuren’s ‘Willy Wonka’ voucher shows how a piece of paper can be worth US$50mNovember 6 at 9:32 PM | msn.comAnalysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), NeoGenomics (NEO)November 6 at 11:27 AM | markets.businessinsider.comThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.November 8, 2024 | Behind the Markets (Ad)Neuren Pharmaceuticals Updates Policy Amid Financial GrowthNovember 1, 2024 | markets.businessinsider.comNeuren Pharmaceuticals Limited (NURPF) Gets a Buy from WilsonsOctober 9, 2024 | markets.businessinsider.com3 Undervalued Small Caps In Australia With Insider ActionOctober 1, 2024 | sg.finance.yahoo.comPCI Biotech Holding ASA (4QG.F)August 29, 2024 | finance.yahoo.comCanaccord Genuity Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)August 19, 2024 | markets.businessinsider.comSee More Headlines NURPF Stock Analysis - Frequently Asked Questions How have NURPF shares performed this year? Neuren Pharmaceuticals' stock was trading at C$16.98 at the beginning of the year. Since then, NURPF stock has decreased by 50.2% and is now trading at C$8.45. View the best growth stocks for 2024 here. How do I buy shares of Neuren Pharmaceuticals? Shares of NURPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NURPF CUSIPN/A CIKN/A Webwww.neurenpharma.com Phone(139) 092-0480FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (OTCMKTS:NURPF) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredUrgent: This election is riggedToday, I want to show you how all these warning signs are converging… and how they’re about to reach a breakin...Porter & Company | SponsoredWhat Trump’s victory means for GOLDGold may have suffered a pullback after news of Trump's 2024 election win spread... But don't be mistaken: ...Stansberry Research | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.